Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen
Executive Summary
Commercial insurers are unlikely to follow CMS' recent national coverage determination on erythropoiesis-stimulating agents for non-renal disease uses, Amgen is predicting
You may also be interested in...
ASCO/ASH Guideline Preserves Higher ESA Dosing Options For Cancer Patients
Despite the emergence of safety concerns related to use of erythropoiesis-stimulating agents in recent years, the American Society of Hematology and the American Society of Clinical Oncology are essentially providing the same dosing recommendations in their latest guideline for treatment of chemotherapy-induced anemia as in the previous version from five years ago
ASCO/ASH Guideline Preserves Higher ESA Dosing Options For Cancer Patients
Despite the emergence of safety concerns related to use of erythropoiesis-stimulating agents in recent years, the American Society of Hematology and the American Society of Clinical Oncology are essentially providing the same dosing recommendations in their latest guideline for treatment of chemotherapy-induced anemia as in the previous version from five years ago
Medicare ESA Policy May Find Support In FDA Letter But J&J Sees Differently
Key Democratic legislators are spotlighting an FDA letter on erythropoiesis-stimulating agents as indicating agreement between FDA and Medicare policies, but some stakeholders interpret it as pointing out differences between the agencies